G. J. Gasic, T. B. Gasic, and C. C. Stewart, Antimetastatic effects associated with platelet reduction, Proc. Natl. Acad. Sci. U. S. A, vol.61, pp.46-52, 1968.

S. Karpatkin, E. Pearlstein, P. L. Salk, and G. Yogeeswaran, Role of platelets in tumor cell metastases, Ann. N. Y. Acad. Sci, vol.370, pp.101-118, 1981.

M. L. Nierodzik, A. Klepfish, and S. Karpatkin, Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo, Thromb. Haemost, vol.74, pp.282-290, 1995.

L. J. Gay and B. , Felding-Habermann, Contribution of platelets to tumour metastasis, Nat. Rev. Cancer, vol.11, pp.123-134, 2011.

G. Gasic and T. Gasic, Removal of sialic acid from the cell coat in tumor cells and vascular endothelium, and its effects on metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.48, pp.1172-1177, 1962.

B. Ho-tin-noé, T. Goerge, S. M. Cifuni, D. Duerschmied, and D. D. Wagner, Platelet granule secretion continuously prevents intratumor hemorrhage, Cancer Res, vol.68, pp.6851-6858, 2008.

E. Camerer, A. A. Qazi, D. N. Duong, I. Cornelissen, R. Advincula et al., Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis, Blood, vol.104, pp.397-401, 2004.

N. M. Bambace and C. E. Holmes, The platelet contribution to cancer progression, J. Thromb. Haemost. JTH, vol.9, pp.237-249, 2011.

A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, J. Thromb. Haemost. JTH, vol.5, pp.632-634, 2007.

J. Levin and C. L. Conley, THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE, vol.114, pp.497-500, 1964.

E. Heinmöller, T. Schropp, O. Kisker, B. Simon, R. Seitz et al., Tumor cellinduced platelet aggregation in vitro by human pancreatic cancer cell lines, Scand. J. Gastroenterol, vol.30, pp.1008-1016, 1995.

E. Heinmöller, R. J. Weinel, H. H. Heidtmann, U. Salge, R. Seitz et al., Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines, J. Cancer Res. Clin. Oncol, vol.122, pp.735-744, 1996.

E. Pearlstein, P. L. Salk, G. Yogeeswaran, S. Karpatkin, ;. Ruf et al., Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, Thromb. Res, vol.125, issue.2, pp.70010-70014, 2010.

J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La-jeunesse, M. J. Flick et al., Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells, Blood, vol.105, pp.178-185, 2005.

E. Pearlstein, C. Ambrogio, G. Gasic, and S. Karpatkin, Inhibition of the plateletaggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide, Prog. Clin. Biol. Res, vol.89, pp.479-502, 1982.

M. T. Nieman, G. Larusch, C. Fang, Y. Zhou, and A. H. Schmaier, Oral thrombostatin FM19 inhibits prostate cancer, Thromb. Haemost, vol.104, pp.1044-1048, 2010.

P. Mehta, D. Lawson, M. B. Ward, L. Lee-ambrose, and A. Kimura, Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation, Cancer Res, vol.46, pp.5061-5063, 1986.

S. Gebremeskel, T. Levatte, R. S. Liwski, B. Johnston, and M. Bezuhly, The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer, Int. J. Cancer J. Int. Cancer, vol.136, pp.234-240, 2015.

S. Mezouar, R. Darbousset, F. Dignat-george, L. Panicot-dubois, and C. Dubois, Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo, Int. J. Cancer J. Int. Cancer, vol.136, pp.462-475, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01773064

O. Uluçkan, M. C. Eagleton, D. H. Floyd, E. A. Morgan, A. C. Hirbe et al., APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice, J. Cell. Biochem, vol.104, pp.1311-1323, 2008.

M. C. Mah-becherel, J. Céraline, G. Deplanque, M. Chenard, J. Bergerat et al.,

. Cazenave, Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model, Br. J. Cancer, vol.86, pp.803-810, 2002.

H. Bando, T. Yamashita, and E. Tsubura, Effects of antiplatelet agents on pulmonary metastases, Gan, vol.75, pp.284-291, 1984.

E. Bastida, G. Escolar, L. Almirall, and A. Ordinas, Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine, Thromb. Haemost, vol.55, pp.333-337, 1986.

L. Lian, W. Li, Z. Li, Y. Mao, Y. Zhang et al., Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs, Oncol. Lett, vol.5, pp.675-680, 2013.

N. M. Bambace, J. E. Levis, and C. E. Holmes, The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets, Platelets, vol.21, pp.85-93, 2010.

J. A. Coppinger, R. O'connor, K. Wynne, M. Flanagan, M. Sullivan et al., Moderation of the platelet releasate response by aspirin, Blood, vol.109, pp.4786-4792, 2007.

F. Ogawa, H. Amano, Y. Ito, Y. Matsui, K. Hosono et al., Aspirin reduces lung cancer metastasis to regional lymph nodes, Biomed. Pharmacother. Bioméd. Pharmacothérapie, vol.68, pp.79-86, 2014.

C. Medina, S. Harmon, I. Inkielewicz, M. J. Santos-martinez, M. Jones et al., Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin, Br. J. Pharmacol, vol.166, pp.938-949, 2012.

G. Sitia, R. Aiolfi, P. D. Lucia, M. Mainetti, A. Fiocchi et al., Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B, Proc. Natl. Acad. Sci. U. S. A, vol.109, pp.2165-2172, 2012.

E. M. Battinelli, B. A. Markens, and J. E. Italiano, Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis, Blood, vol.118, pp.1359-1369, 2011.

N. M. Vad, S. K. Kudugunti, H. Wang, G. J. Bhat, and M. Y. Moridani, Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med, vol.35, pp.4967-4976, 2014.

O. Arrieta, P. Guevara, S. Reyes, G. Palencia, E. Rivera et al., Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system, J. Cancer Res. Clin. Oncol, vol.127, pp.681-686, 2001.

D. Alonso-escolano, A. Y. Strongin, A. W. Chung, E. I. Deryugina, and M. W. Radomski, Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins, Br. J. Pharmacol, vol.141, pp.241-252, 2004.

L. Lian, W. Li, Z. Li, Y. Mao, Y. Zhang et al., Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs, Oncol. Lett, vol.5, pp.675-680, 2013.

R. L. Stone, A. M. Nick, I. A. Mcneish, F. Balkwill, H. D. Han et al., Paraneoplastic thrombocytosis in ovarian cancer, N. Engl. J. Med, vol.366, pp.610-618, 2012.

M. Yan and P. Jurasz, The role of platelets in the tumor microenvironment: From solid tumors to leukemia, Biochim. Biophys. Acta, 2015.

R. Li, M. Ren, N. Chen, M. Luo, X. Deng et al., Presence of intratumoral platelets is associated with tumor vessel structure and metastasis, BMC Cancer, vol.14, p.167, 2014.

U. Rodeck and M. Herlyn, Growth factors in melanoma, Cancer Metastasis Rev, vol.10, pp.89-101, 1991.

H. Yu and T. Rohan, Role of the insulin-like growth factor family in cancer development and progression, J. Natl. Cancer Inst, vol.92, pp.1472-1489, 2000.

D. J. Hicklin and L. M. Ellis, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, pp.1011-1027, 2005.

C. L. Arteaga, T. D. Brown, J. G. Kuhn, H. S. Shen, T. J. O'rourke et al., Phase I clinical and pharmacokinetic trial of Brequinar sodium, Cancer Res, vol.785, pp.4648-4653, 1989.

M. Pollak, M. J. Blouin, J. C. Zhang, and J. J. Kopchick, Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist, Br. J. Cancer, vol.85, pp.428-430, 2001.

K. E. Friend, Cancer and the potential place for growth hormone receptor antagonist therapy, Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc, vol.11, pp.121-123, 2001.

S. P. Dineen, C. L. Roland, J. E. Toombs, M. Kelher, C. C. Silliman et al., The acellular fraction of stored platelets promotes tumor cell invasion, J. Surg. Res, vol.153, pp.132-137, 2009.

B. Sloan and N. S. Scheinfeld, Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy, Curr. Opin. Investig. Drugs Lond. Engl, vol.9, pp.1324-1335, 2000.

J. M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res, vol.60, pp.2178-2189, 2000.

O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li et al., Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248, Mol. Cancer Ther, vol.5, pp.1280-1289, 2006.

C. L. Arteaga, S. D. Hurd, A. R. Winnier, M. D. Johnson, B. M. Fendly et al., Antitransforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression, J. Clin. Invest, vol.92, pp.2569-2576, 1993.

S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He et al., Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factorreceptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice, Cancer Res, vol.64, pp.4201-4208, 2004.

X. Jiang, C. M. Dutton, W. Ning-qi, J. A. Block, P. Brodt et al., Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma, J. Orthop. Res. Off. Publ. Orthop. Res. Soc, vol.21, issue.03, pp.79-81, 2003.

M. Balbín, A. Fueyo, A. M. Tester, A. M. Pendás, A. S. Pitiot et al., Loss of collagenase-2 confers increased skin tumor susceptibility to male mice, Nat. Genet, vol.35, pp.252-257, 2003.

T. Itoh, M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto et al., Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res, vol.58, pp.1048-1051, 1998.

H. B. Acuff, K. J. Carter, B. Fingleton, D. L. Gorden, and L. M. Matrisian, Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment, Cancer Res, vol.66, pp.259-266, 2006.

J. Kim, E. Noh, K. Kwon, J. Kim, Y. You et al., Suppression of TPA-induced tumor cell invasion by sulfuretin via inhibition of NF-?Bdependent MMP-9 expression, Oncol. Rep, vol.29, pp.1231-1237, 2013.

L. Devy, L. Huang, L. Naa, N. Yanamandra, H. Pieters et al., Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res, vol.69, pp.1517-1526, 2009.

E. I. Deryugina and J. P. Quigley, Matrix metalloproteinases and tumor metastasis, Cancer Metastasis Rev, vol.25, pp.9-34, 2006.

T. N. Mitropoulou, G. N. Tzanakakis, D. Kletsas, H. P. Kalofonos, and N. K. Karamanos, Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells, Int. J. Cancer J. Int. Cancer, vol.104, pp.155-160, 2003.

F. Xu, Z. Ou-yang, S. Zhang, D. Song, R. Shao et al., Sodium caffeate induces endothelial cell apoptosis and inhibits VEGF expression in cancer cells, Yao Xue Xue Bao, vol.41, pp.572-576, 2006.

S. Massberg, I. Konrad, K. Schürzinger, M. Lorenz, S. Schneider et al., Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo, J. Exp. Med, vol.203, pp.1221-1233, 2006.

B. A. Teicher and S. P. Fricker, SDF-1)/CXCR4 pathway in cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.12, pp.2927-2931, 2010.

M. S. Cho, J. Bottsford-miller, H. G. Vasquez, R. Stone, B. Zand et al., Platelets increase the proliferation of ovarian cancer cells, Blood, vol.120, pp.4869-4872, 2012.

Z. Wang and H. Huang, Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy, Cancer Lett, vol.331, pp.147-153, 2013.

G. M. Ibele, N. E. Kay, G. J. Johnson, and H. S. Jacob, Human platelets exert cytotoxic effects on tumor cells, Blood, vol.65, pp.1252-1255, 1985.

M. Trikha, Z. Zhou, J. Timar, E. Raso, M. Kennel et al., Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis, Cancer Res, vol.62, pp.2824-2833, 2002.

J. Folkman, E. Merler, C. Abernathy, and G. Williams, Isolation of a tumor factor responsible for angiogenesis, J. Exp. Med, vol.133, pp.275-288, 1971.

N. Nishida, H. Yano, T. Nishida, T. Kamura, and M. Kojiro, Angiogenesis in cancer, Vasc. Health Risk Manag, pp.213-219, 2006.

P. Jurasz, D. Alonso-escolano, and M. W. Radomski, Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation, Br. J. Pharmacol, vol.143, pp.819-826, 2004.

S. Sabrkhany, A. W. Griffioen, and M. G. Egbrink, The role of blood platelets in tumor angiogenesis, Biochim. Biophys. Acta, vol.1815, pp.189-196, 2011.

E. Pipili-synetos, E. Papadimitriou, and M. E. Maragoudakis, Evidence that platelets promote tube formation by endothelial cells on matrigel, Br. J. Pharmacol, vol.125, pp.1252-1257, 1998.

A. Brill, O. Dashevsky, J. Rivo, Y. Gozal, and D. Varon, Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization, Cardiovasc. Res, vol.67, pp.30-38, 2005.

A. Brill, H. Elinav, and D. Varon, Differential role of platelet granular mediators in angiogenesis, Cardiovasc. Res, vol.63, pp.226-235, 2004.

J. Kisucka, C. E. Butterfield, D. G. Duda, S. C. Eichenberger, S. Saffaripour et al., Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage, Proc. Natl. Acad. Sci. U. S. A, vol.103, pp.855-860, 2006.

C. Kut, F. Mac-gabhann, and A. S. Popel, Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, Br. J. Cancer, vol.97, pp.978-985, 2007.

W. Jelkmann, Pitfalls in the measurement of circulating vascular endothelial growth factor, Clin. Chem, vol.47, pp.617-623, 2001.

D. Buergy, F. Wenz, C. Groden, and M. A. Brockmann, Tumor-platelet interaction in solid tumors, Int. J. Cancer J. Int. Cancer, vol.130, pp.2747-2760, 2012.

A. Zaslavsky, K. Baek, R. C. Lynch, S. Short, J. Grillo et al., Plateletderived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis, Blood, vol.115, pp.4605-4613, 2010.

J. E. Italiano, J. L. Richardson, S. Patel-hett, E. Battinelli, A. Zaslavsky et al., Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released, Blood, vol.111, pp.1227-1233, 2008.

A. F. Chambers, A. C. Groom, and I. C. Macdonald, Dissemination and growth of cancer cells in metastatic sites, Nat. Rev. Cancer, vol.2, pp.563-572, 2002.

I. J. Fidler, Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine, J. Natl. Cancer Inst, vol.45, pp.773-782, 1970.

H. Shau, M. D. Roth, and S. H. Golub, Regulation of natural killer function by nonlymphoid cells, Nat. Immun, vol.12, pp.235-249, 1993.

S. Jain, S. Russell, and J. Ware, Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models, J. Thromb. Haemost. JTH, vol.7, pp.1713-1717, 2009.

L. Erpenbeck and M. P. Schön, Deadly allies: the fatal interplay between platelets and metastasizing cancer cells, Blood, vol.115, pp.3427-3436, 2010.

H. Läubli and L. Borsig, Selectins promote tumor metastasis, Semin. Cancer Biol, vol.20, pp.169-177, 2010.

R. M. Nelson, O. Cecconi, W. G. Roberts, A. Aruffo, R. J. Linhardt et al., Heparin oligosaccharides bind L-and P-selectin and inhibit acute inflammation, Blood, vol.82, pp.3253-3258, 1993.

N. M. Varki and A. Varki, Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans, Semin. Thromb. Hemost, vol.28, pp.53-66, 2002.

L. Borsig, R. Wong, J. Feramisco, D. R. Nadeau, N. M. Varki et al., Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.3352-3357, 2001.

M. M. Fuster, J. R. Brown, L. Wang, and J. D. Esko, A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells, Cancer Res, vol.63, pp.2775-2781, 2003.

L. Borsig, R. Wong, R. O. Hynes, N. M. Varki, and A. Varki, Synergistic effects of L-and Pselectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.99, pp.2193-2198, 2002.

J. P. Stone and D. D. Wagner, P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer, J. Clin. Invest, vol.92, pp.804-813, 1993.

Y. J. Kim, L. Borsig, N. M. Varki, and A. Varki, P-selectin deficiency attenuates tumor growth and metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.9325-9330, 1998.

H. Läubli and L. Borsig, Selectins as mediators of lung metastasis, Cancer Microenviron. Off. J. Int. Cancer Microenviron. Soc, vol.3, pp.97-105, 2010.

G. Mannori, P. Crottet, O. Cecconi, K. Hanasaki, A. Aruffo et al., Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins, Cancer Res, vol.55, pp.4425-4431, 1995.

E. O. Kozlowski, M. S. Pavao, and L. Borsig, Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin, J. Thromb. Haemost. JTH, vol.9, pp.1807-1815, 2011.

S. Karpatkin, E. Pearlstein, C. Ambrogio, and B. S. Coller, Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo, J. Clin. Invest, vol.81, pp.1012-1019, 1988.

W. Zhang, S. Dang, T. Hong, J. Tang, J. Fan et al., A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment, Blood, vol.120, pp.2889-2898, 2012.

S. J. Bakewell, P. Nestor, S. Prasad, M. H. Tomasson, N. Dowland et al., Platelet and osteoclast beta3 integrins are critical for bone metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.14205-14210, 2003.

H. Kitagawa, N. Yamamoto, K. Yamamoto, K. Tanoue, G. Kosaki et al., Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells, Cancer Res, vol.49, pp.537-541, 1989.

A. Amirkhosravi, S. A. Mousa, M. Amaya, S. Blaydes, H. Desai et al., Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454, Thromb. Haemost, vol.90, pp.549-554, 2003.

A. Boucharaba, C. Serre, S. Grès, J. S. Saulnier-blache, J. Bordet et al., Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer, J. Clin. Invest, vol.114, pp.1714-1725, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00110127

L. Erpenbeck, B. Nieswandt, M. Schön, M. Pozgajova, and M. P. Schön, Inhibition of platelet GPIb alpha and promotion of melanoma metastasis, J. Invest. Dermatol, vol.130, pp.576-586, 2010.

S. Jain, M. Zuka, J. Liu, S. Russell, J. Dent et al., Platelet glycoprotein Ib alpha supports experimental lung metastasis, Proc. Natl. Acad. Sci. U. S. A, vol.104, pp.9024-9028, 2007.

M. Labelle, S. Begum, and R. O. Hynes, Platelets guide the formation of early metastatic niches, Proc. Natl. Acad. Sci. U. S. A, vol.111, pp.3053-3061, 2014.

A. Palumbo, A. Bertola, P. Musto, T. Caravita, V. Callea et al., Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma, Cancer, vol.104, pp.1428-1433, 2005.

W. J. Storkus and J. R. Dawson, Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules, Crit. Rev. Immunol, vol.10, pp.393-416, 1991.

N. Hanna, The role of natural killer cells in the control of tumor growth and metastasis, Biochim. Biophys. Acta, vol.780, pp.213-226, 1985.

B. Nieswandt, M. Hafner, B. Echtenacher, and D. N. Männel, Lysis of tumor cells by natural killer cells in mice is impeded by platelets, Cancer Res, vol.59, pp.1295-1300, 1999.

K. Palucka and J. Banchereau, Cancer immunotherapy via dendritic cells, Nat. Rev. Cancer, vol.12, pp.265-277, 2012.

K. Imai, S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi, Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population, Lancet, vol.356, pp.1795-1799, 2000.

T. Placke, M. Örgel, M. Schaller, G. Jung, H. Rammensee et al., Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells, Cancer Res, vol.72, pp.440-448, 2012.

J. Tímár, J. Tóvári, E. Rásó, L. Mészáros, B. Bereczky et al., Platelet-mimicry of cancer cells: epiphenomenon with clinical significance, Oncology, vol.69, pp.185-201, 2005.

C. L. Chaffer and R. A. Weinberg, A perspective on cancer cell metastasis, Science, vol.331, pp.1559-1564, 2011.

D. Sharma, K. E. Brummel-ziedins, B. A. Bouchard, and C. E. Holmes, Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer, J. Cell. Physiol, vol.229, pp.1005-1015, 2014.

S. J. Shattil, C. Kim, and M. H. Ginsberg, The final steps of integrin activation: the end game, Nat. Rev. Mol. Cell Biol, vol.11, pp.288-300, 2010.

J. S. Desgrosellier and D. A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities, Nat. Rev. Cancer, vol.10, pp.9-22, 2010.

A. Klepfish, M. A. Greco, and S. Karpatkin, Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix, Int. J. Cancer J. Int. Cancer, vol.53, pp.978-982, 1993.

C. L. Hall, C. W. Dubyk, T. A. Riesenberger, D. Shein, E. T. Keller et al., Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase, Neoplasia N. Y. N, vol.10, pp.797-803, 2008.

D. Schumacher, B. Strilic, K. K. Sivaraj, N. Wettschureck, and S. Offermanns, Plateletderived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor, Cancer Cell, vol.24, pp.130-137, 2013.

G. Skolnik, U. Bagge, A. Dahlström, and H. Ahlman, The importance of 5-HT for tumor cell lodgement in the liver, Int. J. Cancer J. Int. Cancer, vol.33, pp.519-523, 1984.

M. H. Sarker, D. Hu, and P. A. Fraser, Regulation of cerebromicrovascular permeability by lysophosphatidic acid, vol.17, pp.39-46, 1994.

M. Umezu-goto, J. Tanyi, J. Lahad, S. Liu, S. Yu et al., Lysophosphatidic acid production and action: validated targets in cancer?, J. Cell. Biochem, vol.92, pp.1115-1140, 2004.

W. H. Moolenaar, Development of our current understanding of bioactive lysophospholipids, Ann. N. Y. Acad. Sci, vol.905, pp.1-10, 2000.

M. Rolli, E. Fransvea, J. Pilch, A. Saven, and B. , Felding-Habermann, Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells, Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.9482-9487, 2003.

C. Anderberg, S. I. Cunha, Z. Zhai, E. Cortez, E. Pardali et al., Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination, J. Exp. Med, vol.210, pp.563-579, 2013.

W. F. Sindelar, T. S. Tralka, and A. S. Ketcham, Electron microscopic observations on formation of pulmonary metastases, J. Surg. Res, vol.18, pp.137-161, 1975.

R. M. Hoffman, Green fluorescent protein to visualize cancer progression and metastasis, Methods Enzymol, vol.302, pp.20-31, 1999.

A. Yamamoto, S. Yano, M. Shiraga, H. Ogawa, H. Goto et al., A thirdgeneration matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice, Int. J. Cancer J. Int. Cancer, vol.103, pp.822-828, 2003.

B. L. Tranum and A. Haut, Thrombocytosis: platelet kinetics in neoplasia, J. Lab. Clin. Med, vol.84, pp.615-619, 1974.

R. J. Lin, V. Afshar-kharghan, and A. I. Schafer, Paraneoplastic thrombocytosis: the secrets of tumor self-promotion, Blood, vol.124, pp.184-187, 2014.

J. P. Ferriere, D. Bernard, M. Legros, J. Chassagne, P. Chollet et al., beta-Thromboglobulin in patients with breast cancer, Am. J. Hematol, vol.19, pp.47-53, 1985.

T. Yazaki, H. Inage, T. Iizumi, A. Koyama, S. Kanoh et al., Studies on platelet function in patients with prostatic cancer, Urology, vol.30, pp.60-63, 1987.

M. Mantur, H. Kemona, R. Koz?owski, and I. Kemona-chetnik, Effect of tumor stage and nephrectomy on CD62P expression and sP-selectin concentration in renal cancer, Neoplasma, vol.50, pp.262-265, 2003.

F. Tas, D. Duranyildiz, H. O. Soydinc, I. Cicin, M. Selam et al., Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer, Cancer Chemother. Pharmacol, vol.61, pp.721-725, 2008.

S. Mezouar, D. Mege, R. Darbousset, D. Farge, P. Debourdeau et al., Involvement of Platelet-Derived Microparticles in Tumor Progression and Thrombosis, Semin. Oncol, vol.41, pp.346-358, 2014.

H. K. Kim, K. S. Song, Y. S. Park, Y. H. Kang, Y. J. Lee et al., Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor, Eur. J. Cancer Oxf. Engl, vol.39, pp.184-191, 1990.

D. Helley, E. Banu, A. Bouziane, A. Banu, F. Scotte et al., Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy, Eur. Urol, vol.56, pp.479-484, 2009.

A. C. Matzdorff, G. Kühnel, B. Kemkes-matthes, and H. Pralle, Quantitative assessment of platelets, platelet microparticles, and platelet aggregates with flow cytometry, J. Lab. Clin. Med, vol.131, pp.507-517, 1998.

A. A. Khorana, C. W. Francis, E. Culakova, and G. H. Lyman, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer, vol.104, pp.2822-2829, 2005.

C. Ay, R. Simanek, R. Vormittag, D. Dunkler, G. Alguel et al., High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS), Blood, vol.112, pp.2703-2708, 2008.

H. Mutlu, T. A. Artis, A. Erden, and Z. Akca, Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis, Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb, vol.19, pp.331-333, 2013.

A. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, vol.111, pp.4902-4907, 2008.

I. Pabinger, J. Thaler, and C. Ay, Biomarkers for prediction of venous thromboembolism in cancer, Blood, vol.122, pp.2011-2018, 2013.

K. Vanschoonbeek, M. A. Feijge, R. J. Van-kampen, H. Kenis, H. C. Hemker et al., Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics, J. Thromb. Haemost. JTH, vol.2, pp.476-484, 2004.

M. Wahrenbrock, L. Borsig, D. Le, N. Varki, and A. Varki, Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas, J. Clin. Invest, vol.112, pp.853-862, 2003.

J. H. Clark, N. P. Kinnear, S. Kalujnaia, G. Cramb, S. Fleischer et al., Identification of functionally segregated sarcoplasmic reticulum calcium stores in pulmonary arterial smooth muscle, J. Biol. Chem, vol.285, pp.13542-13549, 2010.

M. Demers and D. D. Wagner, Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression, Oncoimmunology, vol.2, p.22946, 2013.

A. M. Algra and P. M. Rothwell, Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol, vol.13, issue.12, pp.70112-70114, 2012.

T. Stürmer, R. J. Glynn, I. M. Lee, J. E. Manson, J. E. Buring et al., Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study, Ann. Intern. Med, vol.128, pp.713-720, 1998.

N. R. Cook, I. Lee, J. M. Gaziano, D. Gordon, P. M. Ridker et al., Lowdose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial, JAMA, vol.294, pp.47-55, 2005.

, Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients, BMJ, vol.308, pp.235-246, 1994.

K. Lacut, J. Van-der-maaten, G. L. Gal, G. Cornily, D. Mottier et al., Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study, Haematologica, vol.93, pp.1117-1118, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00685495

C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini et al., Aspirin for preventing the recurrence of venous thromboembolism, N. Engl. J. Med, vol.366, pp.1959-1967, 2012.

T. A. Brighton, J. W. Eikelboom, K. Mann, R. Mister, A. Gallus et al., Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism, N. Engl. J. Med, vol.367, pp.1979-1987, 2012.

A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano et al., Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.29, pp.986-993, 2011.

I. I. Wistuba, J. G. Gelovani, J. J. Jacoby, S. E. Davis, and R. S. Herbst, Methodological and practical challenges for personalized cancer therapies, Nat. Rev. Clin. Oncol, vol.8, pp.135-141, 2011.